NO962346L - Humaniserte antistoffer og anvendelser derav - Google Patents

Humaniserte antistoffer og anvendelser derav

Info

Publication number
NO962346L
NO962346L NO962346A NO962346A NO962346L NO 962346 L NO962346 L NO 962346L NO 962346 A NO962346 A NO 962346A NO 962346 A NO962346 A NO 962346A NO 962346 L NO962346 L NO 962346L
Authority
NO
Norway
Prior art keywords
antibodies
humanized antibodies
islets
bound
preparation
Prior art date
Application number
NO962346A
Other languages
English (en)
Other versions
NO962346D0 (no
Inventor
Yee-Tharn Augustine Lin
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of NO962346D0 publication Critical patent/NO962346D0/no
Publication of NO962346L publication Critical patent/NO962346L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Humaniserte antistoffer og bindingsproteiner derav med evne til å bli bundet til T-celler som utviser spesielle variable ø-kjeder, og spesielt subpopula- sjoner som uttrykker human VS 5.2 og/eller 5.3 og Ve 8.1. Det er- også beskrevet fremstilling av slike antistoffer, farmasøytiske sammensetninger som Inneholder disse og terapeutisk anvendelse av anti- stoffer, spesielt l autolmmune sykdommer.
NO962346A 1993-12-08 1996-06-05 Humaniserte antistoffer og anvendelser derav NO962346L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939325182A GB9325182D0 (en) 1993-12-08 1993-12-08 Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
PCT/IB1994/000387 WO1995016038A2 (en) 1993-12-08 1994-11-21 Humanized antibodies and uses thereof

Publications (2)

Publication Number Publication Date
NO962346D0 NO962346D0 (no) 1996-06-05
NO962346L true NO962346L (no) 1996-08-06

Family

ID=10746330

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962346A NO962346L (no) 1993-12-08 1996-06-05 Humaniserte antistoffer og anvendelser derav

Country Status (24)

Country Link
US (1) US5861155A (no)
EP (1) EP0737250A1 (no)
JP (1) JPH09509307A (no)
KR (2) KR100239607B1 (no)
CN (1) CN1063792C (no)
AU (1) AU699249B2 (no)
BR (1) BR9408278A (no)
CA (1) CA2178622A1 (no)
CZ (2) CZ287347B6 (no)
EE (1) EE03271B1 (no)
FI (1) FI962377A (no)
GB (1) GB9325182D0 (no)
HU (1) HUT75553A (no)
IL (1) IL111926A (no)
LV (1) LV11631B (no)
NO (1) NO962346L (no)
NZ (1) NZ276170A (no)
PL (1) PL180157B1 (no)
RU (1) RU2139934C1 (no)
SG (1) SG48420A1 (no)
SK (1) SK73596A3 (no)
UA (1) UA29494C2 (no)
WO (1) WO1995016038A2 (no)
ZA (1) ZA949341B (no)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
CN1064052C (zh) * 1997-09-29 2001-04-04 中国科学院微生物研究所 甲状旁腺素相关蛋白人源化抗体及其制备方法
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
GB9906233D0 (en) * 1999-03-19 1999-05-12 Univ Newcastle Bone formation
AU2002213398A1 (en) * 2000-10-20 2002-05-06 Whitehead Institute For Biomedical Research Expression vectors and uses thereof
AU2003221118A1 (en) * 2002-03-22 2003-10-08 Bipha Corporation Immunoglobulin/hydrophilic peptide complexes
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
GB0302740D0 (en) * 2003-02-06 2003-03-12 Axis Shield Asa Assay
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
BRPI0418766B8 (pt) * 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
US7741448B2 (en) * 2005-06-21 2010-06-22 Medical & Biological Laboratories Co., Ltd. Antibody having inhibitory effect on amyloid fibril formation
KR100740201B1 (ko) * 2005-10-21 2007-07-18 삼성전자주식회사 듀얼 전송 스트림 생성 장치 및 그 방법
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US7901687B2 (en) * 2006-04-28 2011-03-08 Eth Zurich Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US20080003230A1 (en) 2006-07-03 2008-01-03 Adair Charles D Composition for modulating the expression of cell adhesion molecules
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
KR101581279B1 (ko) * 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
DK2164992T3 (en) * 2007-05-30 2016-08-15 Lpath Inc COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
GB2465907B (en) 2007-08-10 2013-07-10 Agency Science Tech & Res VHZ for diagnosis and treatment of cancer
EP2201040A1 (en) * 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2331107A4 (en) * 2008-08-08 2011-08-24 Agency Science Tech & Res VHZ FOR DIAGNOSIS AND TREATMENT OF CANCERS
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010065437A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
KR20110097923A (ko) * 2008-12-05 2011-08-31 엘파스, 인크. 항-지질 항체 결정 구조를 이용한 항체 설계
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2400981A4 (en) * 2009-02-26 2013-02-27 Lpath Inc DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES
EP2419446A4 (en) * 2009-04-17 2013-01-23 Lpath Inc HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID
CN102985441B (zh) 2010-02-19 2015-04-22 俄克拉何马大学董事会 抑制Wnt信号传导途径的单克隆抗体及其制备方法和用途
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
CA2822610C (en) 2010-12-21 2019-09-03 Selexys Pharmaceuticals Corporation Use of anti-p-selectin antibodies
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
ES2748577T3 (es) 2011-05-19 2020-03-17 Univ Michigan Regents Agentes de fijación de la integrina alfa-2 y uso de los mismos para inhibir la proliferación de las células de cáncer
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSIS
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
DK2912064T3 (da) 2012-10-24 2019-07-22 Res Found Dev Jam-c-antistoffer og fremgangsmåder til behandling af cancer
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
CN105246501B (zh) 2013-03-27 2021-01-12 雪松-西奈医学中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
US10889637B2 (en) 2016-02-26 2021-01-12 The Board Of Regents Of The University Of Texas System Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2
US11660352B2 (en) 2016-03-29 2023-05-30 Stcube, Inc. Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
KR20190031299A (ko) 2016-07-20 2019-03-25 주식회사 에스티큐브 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
SG11201909751TA (en) 2017-05-12 2019-11-28 Augusta University Research Institute Inc Human alpha fetoprotein-specific t cell receptors and uses thereof
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
GB2581619A (en) 2017-09-15 2020-08-26 Univ California Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
EP3774916A2 (en) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
EP3818083A2 (en) * 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113365697A (zh) 2018-09-25 2021-09-07 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
US20220195024A1 (en) 2018-11-02 2022-06-23 Oklahoma Medical Research Foundation Monoclonal Antibodies to ELTD1 and Uses Thereof
GB2599227B (en) 2019-02-21 2024-05-01 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
GB2599229B (en) * 2019-02-21 2024-04-24 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
WO2020172596A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN115427447A (zh) 2020-01-17 2022-12-02 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
EP4139363A1 (en) 2020-04-24 2023-03-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN116761818A (zh) 2020-08-26 2023-09-15 马伦戈治疗公司 检测trbc1或trbc2的方法
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
CA3203773A1 (en) 2020-12-01 2022-06-09 The Johns Hopkins University Methods and materials for treating t cell cancers
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
WO1989007452A1 (en) * 1988-02-12 1989-08-24 Medical Research Council Improvements in or relating to antibodies
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
ES2112838T5 (es) * 1989-07-19 2004-09-01 Connetics Corporation Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5067193A (en) * 1990-07-26 1991-11-26 Container Graphics Corporation Rotary printing plate washing apparatus
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease

Also Published As

Publication number Publication date
KR100258902B1 (en) 2000-06-15
EP0737250A1 (en) 1996-10-16
GB9325182D0 (en) 1994-02-09
IL111926A0 (en) 1995-03-15
NZ276170A (en) 1998-05-27
LV11631A (lv) 1996-12-20
WO1995016038A3 (en) 1995-07-06
FI962377A0 (fi) 1996-06-07
KR100239607B1 (ko) 2000-01-15
BR9408278A (pt) 1996-12-17
ZA949341B (en) 1996-05-24
IL111926A (en) 2002-07-25
UA29494C2 (uk) 2000-11-15
SK73596A3 (en) 1997-05-07
US5861155A (en) 1999-01-19
CN1142855A (zh) 1997-02-12
AU1033395A (en) 1995-06-27
HUT75553A (en) 1997-05-28
KR960706560A (ko) 1996-12-09
PL180157B1 (en) 2000-12-29
FI962377A (fi) 1996-07-30
HU9601574D0 (en) 1996-07-29
RU2139934C1 (ru) 1999-10-20
PL314908A1 (en) 1996-09-30
CZ287347B6 (en) 2000-10-11
SG48420A1 (en) 1998-04-17
WO1995016038A2 (en) 1995-06-15
NO962346D0 (no) 1996-06-05
CZ162896A3 (en) 1997-01-15
AU699249B2 (en) 1998-11-26
LV11631B (en) 1997-04-20
EE03271B1 (et) 2000-06-15
CZ287298B6 (cs) 2000-10-11
JPH09509307A (ja) 1997-09-22
CN1063792C (zh) 2001-03-28
CA2178622A1 (en) 1995-06-15

Similar Documents

Publication Publication Date Title
NO962346L (no) Humaniserte antistoffer og anvendelser derav
CA2091769A1 (en) Framework mutated antibodies and their preparation
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
AU7095887A (en) Human gamma interferon-specific receptor protein, antibody against said protein and said antibody and compositions containing said protein and antibody
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
CA2128511A1 (en) Monomeric and dimeric antibody-fragment fusion proteins
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
DE68925226D1 (de) Monoklonale Antikörper
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
SE8700467L (sv) Monoklonala humanantikroppberedningar som er korsprotektiva
NO922621L (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
ATE164311T1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
IE871769L (en) Fluorooxirane carboxylates
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
CA2262546A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Nicotra et al. Cation complexed DNA. Immunoadsorption of anti-DNA antibodies by DNA bound to agarose-poly-L-lysine
IL130960A0 (en) Novel ifn receptor 1 binding proteins dna encoding them and methods of modulating cellular response to interferons
AU2328788A (en) Preparation containing high molecular staphylococcal protein; antibody preparation directed against the protein; and the use of the preparations
IL80918A (en) Monoclonal antibodies cross-reactive and cross-protective against p.aeruginosa serotypes and pharmaceutical compositions and kits containing said antibodies
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application